Vitigo 1.5% Cream 10gm

Uses of Vitigo 1.5% Cream

Treatment of Myelofibrosis, polycythaemia vera (PV), and graft-versus-host disease (GVHD)

Side Effects of Vitigo 1.5% Cream

• Urinary tract infection
• Tiredness, fatigue, shortness of breath, pale skin
• Infections, fever, chills, sore throat, and mouth ulcers
• Spontaneous bleeding or bruising
• Painful skin rash with blisters
• Bleeding in the brain (altered level of consciousness, persistent headache, numbness, tingling, weakness and paralysis)
• Bleeding in the stomach or intestine
• Low heartbeat, chest pain, dizziness, vertigo, fainting

How does Vitigo 1.5% Cream work?

Vitigo 1.5% Cream contains Ruxolitinib, a Janus-associated kinase (JAK1 and JAK2) inhibitor that reduces spleen size and alleviates symptoms like fever, bone pain, night sweats, and weight loss in patients with myelofibrosis. In polycythemia vera, it lowers red blood cell production, reducing the risk of serious blood and vascular complications. RUXOLITINIB also improves symptoms and survival in acute and chronic graft-versus-host disease.

Quick Suggestions:

• Always take Ruxolitinib exactly as prescribed by your doctor. Do not change the dosage or stop taking it without consulting your doctor
• Alcohol can interact with Ruxolitinib and increase the risk of side effects. Additionally, grapefruit and grapefruit juice can also interact with the medication, so it's best to avoid them while on this treatment
• Ruxolitinib is usually taken with food to improve its absorption and reduce the risk of stomach upset. Follow your doctor's recommendations regarding food intake
• Ruxolitinib is not recommended for use in pregnant women unless necessary. Discuss the risks and benefits with your doctor
• Ruxolitinib is not recommended for use in breastfeeding women unless necessary. Discuss the risks and benefits with your doctor

Pharmacology

Vitigo inhibits Janus kinase (JAK) pathways, which consist of intracellular tyrosine kinases. These kinases are involved in immune cell function and inflammation associated with conditions like atopic dermatitis. JAK inhibitors prevent the phosphorylation and activation of STATs (signal transducers and activators of transcription), reducing inflammatory signals.

• Absorption: Peak plasma concentration: 449 nM (adults); 110 nM (adolescents).
• Distribution: 97% protein-bound.
• Metabolism: Primarily metabolized by CYP3A4, with lesser involvement of CYP2C9.
• Excretion: Mostly through urine (74%) and feces (22%), with <1% excreted as an unchanged drug.
• Half-life: 116 hours.

Dosage & Administration of Vitigo 1.5% Cream

• For atopic dermatitis: Apply a thin layer of Ruxolitinib (Vitigo) twice daily to affected areas covering up to 20% of the body. Discontinue use when symptoms resolve.
• For nonsegmental vitiligo: Apply a thin layer of Ruxolitinib twice daily to affected areas covering up to 10% of the body surface.

Interaction

• Vitigo is metabolized by CYP3A4. Strong CYP3A4 inhibitors should be avoided, as they may increase Vitigo's systemic exposure and adverse reactions.
• Drug interaction studies were not conducted.

Contraindications

Contraindicated in patients with known hypersensitivity to Ruxolitinib or any of its components.

Pregnancy & Lactation

Vitigo 1.5% Cream may be unsafe to use during pregnancy. Although there are limited studies in humans, animal studies have shown harmful effects on the developing baby. Your doctor will weigh the benefits and any potential risks before prescribing it to you. Please consult your doctor.

Vitigo 1.5% Cream is probably unsafe to use during breastfeeding. Limited human data suggests that the drug may pass into the breastmilk and harm the baby.

Precautions & Warnings

• Serious infections: Serious and sometimes fatal infections, including bacterial, fungal, and viral infections, have been reported with oral JAK inhibitors. Lower respiratory tract infections were noted in the clinical trials of topical Vitigo.
• Viral reactivation: Cases of herpes virus reactivation (e.g., herpes zoster) have been observed with JAK inhibitors.
• Hepatitis B and C: The effect of JAK inhibitors on chronic hepatitis B or C reactivation is unknown. Patients with a history of hepatitis B or C were excluded from clinical trials.

Storage:

Store in a cool and dry place away from sunlight